الفهرس 
No Reflow PhenomenonOnly 14 pages are availabe for public view
 |  | from | 153 |  |  |
| | | from | 153 | | |
Abstract
Background; The best treatment of ST-segment elevation myocardial infarction (STEMI) is reperfusion of ischemic myocardium as soon as possible. Primary percutaneous coronary intervention (PPCI) has become the preferred strategy for reperfusion and the current standard care for STEMI. No-reflow is clinically important as it is associated with cardiac failure, malignant arrhythmias and in-hospital and long-term mortality. Cystatin C is a potent inhibitor of lysosomal proteinases and found in virtually all tissues and body fluids. The aim of this study; To assess the relationship between the level of Cystatin C and the occurrence of no-reflow during primary PCI in the setting of STEMI. Study design; This study was a Case Control Study. Setting; This study was carried out at the cardiology department Ain shams university. Target population: This prospective clinical trial study was conducted on 68 patients with acute STEMI who were undergoing PPCI who were subdivided into 2 groups: group 1: patients with TIMI III flow. group 2: patients with no reflow. Serum cystatin c level was assessed in the group with TIMI III flow VS No reflow group. Result; there was statistically significant difference between reflow and no reflow regarding cystatin c level found higher in no reflow cases than reflow cases. Conclusion; In conclusion, data of this study suggest that Cystatin C is a useful marker for prediction of no-reflow after PCI in STEMI as it can help in screening of STEMI patients with high risk of development of no-reflow on admission and help to choose the best treatment.